Citius Oncology, Inc. Common Stock (CTOR) is a publicly traded Healthcare sector company. As of August 12, 2026, CTOR trades at $0.72 with a market cap of $68.57M and a P/E ratio of -1.55. CTOR moved -2.05% today. Year to date, CTOR is -27.00%; over the trailing twelve months it is -57.56%. Its 52-week range spans $0.49 to $6.19. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces CTOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for CTOR, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $0.72 |
| Market Cap | $68.57M |
| P/E Ratio | -1.55 |
| EPS | $-0.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.19 |
| 52-Week Low | $0.49 |
| Volume | 3.37K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.61M |
| Net Income | $-42.51M |
| Gross Margin | 0.00% |
1 analysts cover CTOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.